- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05629689
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients With Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, PET Imaging, Pharmacokinetics, and Changes in Imaging After Treatment
Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days.
Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment.
Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunotherapy immune-checkpoint inhibitor (ICI) treatment visits and 2 additional imaging and 1 follow-up visit . The estimated duration of Part B is approximately 64 days.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yaron Raiter, MD
- Phone Number: +31 6 21288463
- Email: yaron.raiter@ge.com
Study Contact Backup
- Name: Jane Bateman, RN
- Phone Number: (508) 5730016
- Email: Jane.Bateman@ge.com
Study Locations
-
-
-
Groningen, Netherlands
- Recruiting
- UMC Groningen
-
Contact:
- Derk Jan de Groot, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The subject is able and willing to comply with all study procedures as described in the protocol, including the imaging day pre-visit requirements, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
- The subject is male or female, ≥18 years of age.
- Subject has a life expectancy ≥12 weeks.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Subject has an irresectable or metastatic solid tumour or a local and resectable head and neck squamous cell carcinoma.
- Subject is eligible for ICI treatment.
- Subject is male, or a female who agrees to comply with the protocol contraception method.
Exclusion Criteria:
- Subject is unable to undergo all procedures in the study and/or is unable to remain still and tolerate the imaging procedure.
- Subject has 12-lead ECG significant findings during screening, per Investigator's assessment.
- Subject is not stable due to medical condition or therapy that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject has active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents.
- Subject has any safety laboratory test results (clinical chemistry, haematology, and urinalysis) that, in the opinion of the Investigator, could compromise subject safety or protocol objectives.
- Subject is pregnant or planning to become pregnant or is lactating.
- Subject has a history of alcohol or drug abuse within the last year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A Cohort 1 - 1 mg dose
1 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
|
Experimental: Part A Cohort 2 - 2 mg dose
2 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
|
Experimental: Part A Cohort 3 - 4 mg dose
4 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
|
Experimental: Part A Cohort 4 - 8 mg dose
8 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
|
Experimental: Part A Cohort 5 (optional) - 12 or 15 mg dose
12 or 15 mg mass dose of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
|
Experimental: Part A Cohort 6 - Optimal dose
Selected (optimal) mass dose as determined from results of Cohorts 1 through 5 of GEH200520 Injection with fixed dose of GEH200521 (18F) Injection administered together
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
|
Experimental: Part B
Selected (optimal) dose of GEH200520 Injection from Part A with fixed dose of GEH200521 (18F) Injection administered together in 3 sequential repeat imaging visits
|
Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Whole-body PET/CT scan (up to 30 min).
Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A: The incidence of AEs upon causality to the IMPs.
Time Frame: Part A: 7 days
|
Part A: 7 days
|
Part A: The severity of AEs per National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) upon causality to the IMPs.
Time Frame: Part A: 7 days
|
Part A: 7 days
|
To evaluate the time-course changes in GEH200521 (18F) Injection uptake after immune-checkpoint inhibitor (ICI) treatment cycles compared to baseline.
Time Frame: Part B: 50 days
|
Part B: 50 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the radiation dosimetry of a fixed dose of GEH200521 (18F) Injection when administered with the different GEH200520 Injection mass doses by cumulated activity in source regions and by entire body.
Time Frame: 7 days
|
7 days
|
|
To evaluate the optimal imaging time window for GEH200521 (18F) Injection positron emission tomography (PET) imaging when administered with different GEH200520 Injection mass doses for Part A subjects.
Time Frame: 7 days
|
7 days
|
|
To determine the appropriate mass dose of GEH200520 Injection for administration with GEH200521 (18F) Injection to achieve an acceptable PET image quality for Part A subjects.
Time Frame: 7 days
|
7 days
|
|
To characterize the pharmacokinetic (PK) properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Time Frame: 7 days
|
The PK parameter to be assessed: AUC
|
7 days
|
To characterize the pharmacokinetic (PK) properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Time Frame: 7 days
|
The PK parameter to be assessed: Cmax
|
7 days
|
To characterize the pharmacokinetic (PK) properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Time Frame: 7 days
|
The PK parameter to be assessed: CL
|
7 days
|
To characterize the pharmacokinetic (PK) properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Time Frame: 7 days
|
The PK parameter to be assessed: V
|
7 days
|
To characterize the pharmacokinetic (PK) properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Time Frame: 7 days
|
The PK parameter to be assessed: t1/2
|
7 days
|
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs, for Part A subjects.
Time Frame: 7 days
|
Incidence of AEs, SAEs, and Treatment-emergent AEs by system organ class and preferred term
|
7 days
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Time Frame: Baseline, 24 hours, 7 days post IMP administration
|
The findings in the physical exam pre and post-administration will be summarized.
|
Baseline, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Time Frame: Baseline, 24 hours, 7 days post IMP administration
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit.
The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.
|
Baseline, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
Time Frame: Baseline, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part A subjects.
|
Baseline, 24 hours, 7 days post IMP administration
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Time Frame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized.
|
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Time Frame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized.
|
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Time Frame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized.
|
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part A subjects
Time Frame: Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
Descriptive statistics will be used to describe the observed values and change from baseline.
|
Baseline, 2 hours, 24 hours, 7 days post IMP administration
|
To assess immunogenicity, via the incidence of treatment-induced anti-drug antibodies responses, after a single injection of the different GEH200520 Injection mass doses administered with a fixed dose of GEH200521 (18F) Injection for Part A subjects.
Time Frame: 7 days
|
7 days
|
|
Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs
Time Frame: 50 days
|
50 days
|
|
To assess the biodistribution and tumour uptake of GEH200521 (18F) Injection with the optimal GEH200520 Injection dose determined in Part A based on quantitative measurements of GEH200521 (18F) in regions of interest for Part B subjects.
Time Frame: 50 days
|
50 days
|
|
To assess the relationship between tumour GEH200521 (18F) Injection uptake (SUV value) and immune cell CD8+ expression score from a biopsy sample/resected lesion when available based on IHC results for Part B subjects.
Time Frame: 50 days
|
50 days
|
|
To compare changes in tumour GEH200521 (18F) Injection uptake with changes in computed tomography (CT) image assessment, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for Part B subjects when available .
Time Frame: 50 days
|
50 days
|
|
To compare changes in tumour GEH200521 (18F) Injection uptake with changes in computed tomography (CT) image assessment, according to [18F]-fluorodeoxyglucose (FDG) scans, when available for Part B subjects.
Time Frame: 50 days
|
50 days
|
|
Changes in physical examination status following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Time Frame: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration physical exam status values outside the normal limits will be summarized.
|
Baseline, Day 15, Day 36, Day 50
|
Change from baseline in the results of serum biochemistry test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Time Frame: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit.
The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.
|
Baseline, Day 15, Day 36, Day 50
|
Change from baseline in the results of haematology test results following administration of GEH200520 and GEH200521 (18F) for Part B subjects.
Time Frame: Baseline, Day 15, Day 36, Day 50
|
In this context, baseline is defined as the pre-treatment assessment at the screening visit.
The occurrence of post injection values outside of normal limits and changes from baseline will be summarized.
|
Baseline, Day 15, Day 36, Day 50
|
Changes in heart rate as beats per minute following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Time Frame: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration heart rate values outside the normal limits will be summarized.
|
Baseline, Day 15, Day 36, Day 50
|
Changes in blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Time Frame: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration blood pressure values outside the normal limits will be summarized.
|
Baseline, Day 15, Day 36, Day 50
|
Changes in temperature as degree C following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Time Frame: Baseline, Day 15, Day 36, Day 50
|
The occurrence of post-administration body temperature values outside the normal limits will be summarized.
|
Baseline, Day 15, Day 36, Day 50
|
Change from baseline in the results of 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F) for Part B subjects
Time Frame: Baseline, Day 15, Day 36, Day 50
|
Descriptive statistics will be used to describe the observed values and change from baseline.
|
Baseline, Day 15, Day 36, Day 50
|
To characterize the PK properties (AUC) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Time Frame: 50 days
|
The PK parameter to be assessed: AUC
|
50 days
|
To characterize the PK properties (Cmax) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Time Frame: 50 days
|
The PK parameter to be assessed: Cmax
|
50 days
|
To characterize the PK properties (CL) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Time Frame: 50 days
|
The PK parameter to be assessed: CL
|
50 days
|
To characterize the PK properties (V) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Time Frame: 50 days
|
The PK parameter to be assessed: V
|
50 days
|
To characterize the PK properties (t1/2) of total protein (GEH200520 and [18F]GEH200521 combined) following administration of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Time Frame: 50 days
|
The PK parameter to be assessed: t1/2
|
50 days
|
To compare immunogenicity, via the incidence of treatment-induced anti-drug antibodies responses, after multiple administrations of GEH200520 Injection with GEH200521 (18F) Injection for Part B subjects.
Time Frame: 50 days
|
50 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yaron Raiter, MD, GE Healthcare
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GE-269-001
- 2022-000246-16 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oncology
-
State University of New York at BuffaloRecruitingMedical Oncology | Integrative Oncology | Medical Nutrition TherapyUnited States
-
State University of New York at BuffaloRecruitingMedical Oncology | Integrative Oncology | Medical Nutrition TherapyUnited States
-
MaineHealthTufts Medical CenterRecruitingOncology | Prehabilitation | Surgical OncologyUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmMax Bio, Inc.CompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States
-
Royal Marsden NHS Foundation TrustRecruiting
-
GuerbetRecruitingOncologyAustria, France, Switzerland
-
Centre Hospitalier Regional de HuyCompleted
Clinical Trials on GEH200520 Injection / GEH200521 (18F) Injection - Part A
-
Beijing Biostar Pharmaceuticals Co., Ltd.RecruitingAdvanced Solid TumorChina
-
GE HealthcareQuintiles, Inc.; i3 Statprobe; BIAFFIN GmbH & Co. KG (Biomolecular Interaction...CompletedSarcoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Lung Cancer | Solid Tumors | High Grade GliomasUnited States
-
Alessandro D'AgnoloProgenics Pharmaceuticals, Inc.Active, not recruitingNeoplasms | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Genital Diseases, Male | Prostatic DiseaseUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedMetastatic Prostate CancerUnited States
-
GE HealthcareCompletedIschemic Heart Disease | Coronary Artery Disease (CAD)United States
-
HTA Co., Ltd.Recruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedProstate CancerUnited States
-
GE HealthcareHvidovre University Hospital; Medpace, Inc.; i3 StatprobeCompletedAlzheimer's Disease | Amnestic Mild Cognitive ImpairmentNorway
-
GE HealthcareNational Cancer Institute (NCI)Terminated
-
GE HealthcareCentre for Probe Development and CommercializationCompletedRelapsing-remitting Multiple Sclerosis (rrMS)Canada